Lexeo Therapeutics (LXEO) EBIT (2022 - 2023)
Historic EBIT for Lexeo Therapeutics (LXEO) over the last 2 years, with Q4 2023 value amounting to -$15.0 million.
- Lexeo Therapeutics' EBIT rose 146.74% to -$15.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$68.5 million, marking a year-over-year change of. This contributed to the annual value of -$105.8 million for FY2024, which is 5437.36% down from last year.
- As of Q4 2023, Lexeo Therapeutics' EBIT stood at -$15.0 million, which was up 146.74% from -$20.3 million recorded in Q3 2023.
- In the past 5 years, Lexeo Therapeutics' EBIT registered a high of -$14.0 million during Q2 2023, and its lowest value of -$20.3 million during Q3 2023.